Kowa Research Institute Inc.
- Address
- 430 Davis Drive Suite 200
Sponsor Overview
Specializations
Corneal endothelial disease
Kowa Research Institute Inc. is involved in clinical research for Fuchs endothelial corneal dystrophy, with a focus on preserving and improving visual acuity after corneal procedures. Its studies center on treatment approaches used around descemetorhexis and cataract-related surgery in patients with endothelial dysfunction.
- Fuchs endothelial corneal dystrophy
- Best corrected visual acuity (BCVA)
- Descemetorhexis
- Cataract surgery
The sponsor’s ophthalmic research includes interest in post-procedural recovery and corneal clarity in a setting of progressive endothelial cell loss.
Ophthalmic therapeutics
Within eye disease research, the sponsor evaluates Ripasudil (K-321) for its role in supporting corneal function and improving patient outcomes in Fuchs dystrophy. The therapeutic emphasis is on interventions used after corneal tissue removal procedures and their effect on functional vision.
- Ripasudil (K-321)
- Corneal function
- Post-surgical vision recovery
- Endothelial corneal disease
These studies place the sponsor in the field of ophthalmology, particularly around therapies for corneal degeneration and visual rehabilitation.
Metabolic liver disease
The sponsor also funds research in noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis, reflecting a therapeutic interest in chronic metabolic liver injury and fibrotic progression. The clinical focus is on disease states where inflammation and tissue remodeling contribute to long-term hepatic impairment.
- Noncirrhotic NASH
- Liver fibrosis
- Metabolic liver disease
- Hepatic fibrosis
Its liver-disease portfolio highlights involvement in hepatology and fibrosis-related therapeutic development.
Combination therapy development
In NASH research, Kowa Research Institute Inc. is engaged in studies of combination therapy aimed at addressing fibrotic liver disease through multiple therapeutic mechanisms. This area links metabolic regulation with antifibrotic treatment interests in patients with noncirrhotic liver involvement.
- Combination therapy
- Antifibrotic treatment
- Metabolic regulation
- Chronic liver inflammation
The sponsor’s research activity spans both ocular and hepatic therapeutic domains, with active trial involvement across multiple collaborating sites.
Sponsored Trials
Data & Insights
This sponsor works with 3 molecules, of which 3 are not being studied by other sponsors.
This sponsor has worked with 25 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases2 trials138 other sponsors
- 2.Metabolism1 trial38 other sponsors
Partnered Research Centres
25 centres- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Bulevard Nikola Yonkov Vaptsarov 51b, 1407 Sofia
- Address
- Carrer Del Doctor Joan Soler 1-3, 08243 Manresa
- Address
- Triaditsa, Ulitsa Sveti Georgi Sofiyski 1, 1431 Sofia
- Address
- Calle Del Doctor Esquerdo 46, 28007 Madrid
- Address
- Lugar Jubias De Arriba 84, 15006 A Coruna Galicia
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kowa Research Institute Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.